**Pandoraea pnomenusa** Isolated from an Australian Patient with Cystic Fibrosis

Mark Ambrose¹*, Roslyn C. Malley¹,², Sanchia J. C. Warren³, Sean A. Beggs¹,⁴, Oliver F. E. Swallow¹, Belinda McEwan³, David Stock⁵ and Louise F. Roddam¹

¹ School of Medicine, University of Tasmania, Tasmania, TAS, Australia, ² Department of Pathology, Royal Hobart Hospital, Tasmania, TAS, Australia, ³ Department of Microbiology and Infectious Diseases, Royal Hobart Hospital, Tasmania, TAS, Australia, ⁴ Department of Paediatrics, Royal Hobart Hospital, Tasmania, TAS, Australia, ⁵ Department of Respiratory and General Medicine, Royal Hobart Hospital, Tasmania, TAS, Australia

**Pandoraea** species are considered as emerging pathogens in people with cystic fibrosis (CF). The contribution of these organisms to disease progression in CF patients is not fully understood owing in large measure to the scant reports in clinical and research literature describing their colonization of CF patients and their associated virulence determinants. In an effort to increase awareness and evidence for *Pandoraea* spp. infection in people with CF, and to stimulate research aimed at unraveling the pathogenic properties of *Pandoraea*, we report a case of a 26-year-old Australian (Tasmanian) man with CF who was chronically infected with *Pandoraea pnomenusa* for at least one year prior to his death from respiratory failure. In addition, we describe for the first time evidence suggesting that this bacterium is a facultative anaerobe and report on the availability of a whole genome sequence for this organism. To the best of our knowledge, this report represents only the second clinical case study of *P. pnomenusa* infection in the world, and the first in an Australian CF patient.

**Keywords:** *Pandoraea*, cystic fibrosis, infection, anaerobe, lung

**CASE REPORT**

In January 2013, a 26-year-old man with cystic fibrosis (CF; genotype homozygous F508del) and a history of chronic mucoid *Pseudomonas aeruginosa* lung infection was admitted to the Royal Hobart Hospital (RHH), Tasmania, Australia, with increasing malaise and left-sided pleuritic chest pain. The patient was at the time on his eighth day of out-patient intravenous antibiotic therapy for a respiratory exacerbation, which consisted of once daily tobramycin (560 mg), piperacillin/tazobactam (12 g of piperacillin component/24 h) as a continuous infusion, in addition to his long-term azithromycin (500 mg, orally three times a week) therapy.

On admission he was afebrile with an oxygen saturation of 97% on 4 L/min O₂ via nasal cannulae, and his heart rate was 94 beats per minute with a blood pressure of 116/74 mm Hg. On physical examination, reduced breath sounds and inspiratory crackles were noted in the left lower zone. In addition, his white cell count was elevated (19.7 × 10⁹/L [normal range 3.5–11.0 × 10⁹/L]) with 80.2% neutrophils. A chest radiograph revealed a new and moderately large left pleural effusion. Computed tomography (CT) confirmed the multi-loculated left pleural effusion without contrast enhancement, as well as collapse/consolidation in the basal left upper and lower lobes (Figure 1). On the third day after admission a bronchoscopy and insertion of intercostal catheter (ICC) was performed in theater and serous fluid drained from the ICC. During the bronchoscopy copious purulent secretions were suctioned from the left bronchial tree and bronchial lavage...
performed. The bronchoscopy was complicated by respiratory failure, and consequently the patient was transferred to the intensive care unit (ICU) unit for mechanical ventilation. No bacteria or fungi were able to be recovered from the patient's pleural fluid samples collected at that time. In contrast, 2 Frontiers in Microbiology | www.frontiersin.org No bacteria or fungi were able to be recovered from the intensive care unit (ICU) unit for mechanical ventilation. In February 2012, the patient presented to a local private hospital and a similar multi-resistant sputum isolate was recovered. This isolate was retrospectively identified as \textit{P. apista} by matrix-assisted laser desorption ionization-time of flight mass spectrometry (MALDI-TOF MS, Bruker Daltonics GmbH, Leipzig, Germany) with a score of 2.049, which was indicative of a reliable identification. The isolate was also submitted to the Microbiological Diagnostic Unit Public Health Laboratory (University of Melbourne, Australia) but 16S rRNA gene sequencing and phenotypic testing collectively were only able to identify the isolate as belonging to the genus \textit{Pandoraea}.

In January 2013, the patient's forced expiratory volume in 1 second (FEV1) was lower (55% predicted) than his previous measurement (of 60%, late 2012). Following this diagnosis, the out-patient treatment regimen with tobramycin, piperacillin/tazobactam, and azithromycin was continued. A sputum culture obtained from the patient eight days prior to his presentation and admission to the RHH (in January 2013) showed that he had a persistent poly-microbial airway infection, including \textit{P. aeruginosa}, \textit{Staphylococcus aureus}, \textit{Streptococcus milleri} group, \textit{C. albicans}, and \textit{P. apista}; the identity of this \textit{P. apista} isolate was confirmed by the MALDI-TOF MS, at the RHH. The \textit{P. apista} isolate was subsequently demonstrated to be susceptible to the antibiotics imipenem (by RHH staff) and cotrimoxazole but resistant to ceftazidime, ciprofloxacin, gentamicin, tobramycin, piperacillin-tazobactam, ticarcillin/clavulanic acid (timentin), aztreonam, ceftriaxone, meropenem, colistin, and trimethoprim (Table 1). It is noteworthy that the antibiotic susceptibility profile of this \textit{P. apista} isolate was similar to that obtained for the initial multi-drug resistant isolate recovered from the patient's sputum sample (December 2011). Interestingly, the CF lung environment is characterized by the presence of hypoxic micro-niches yet the ability of \textit{Pandoraea} to colonize these niches is unknown. We demonstrated that

\begin{table}[h]
\centering
\caption{Antibiotic Susceptibility of \textit{P. apista} Isolate from Patient's Sputum Sample.}
\begin{tabular}{|c|c|c|c|c|c|c|c|}
\hline
Antibiotic & Susceptible & Resistant & Intermediate & & & & \\
\hline
\textit{P. aeruginosa} & & & & & & & \\
\textit{Staphylococcus aureus} & & & & & & & \\
\textit{Streptococcus milleri} & & & & & & & \\
\textit{C. albicans} & & & & & & & \\
\textit{P. apista} & & & & & & & \\
\hline
\end{tabular}
\end{table}

FIGURE 1 | A computed tomography (CT) scan showed a multi-loculated left pleural effusion.

MICROBIOLOGY

On a previous (December 2011) presentation to the RHH, a multiple antibiotic resistant isolate was recovered from the patient's sputum sample that was streaked out on a \textit{Burkholderia cepacia}-selective medium. The isolate was presumptively identified as a non-mucoid \textit{P. aeruginosa} but was not stored. A repeat bronchoscopy on day seven showed a much-reduced volume of large airways secretions. A contemporaneous CT showed progressive consolidation and increasing prominence of widespread ground-glass opacities, suspicious for the development of adult respiratory distress syndrome (ARDS). Bronchial washings also showed persistence of mucoid \textit{P. aeruginosa}, \textit{C. albicans}, and \textit{Pandoraea}. In keeping with an advanced directive, active treatment was withdrawn and palliative care commenced. On the 11th day after his admission to the RHH, the patient died.
the *P. apista* isolates were able to grow under anaerobic conditions. BHI agar plates supplemented with 1% potassium nitrate were inoculated with *Pandoraea* cultures and incubated in an anaerobic jar (containing an anaerobic sachet [AN0035; AnaeroGen, Oxoid, UK] and anaerobic indicator) at 37°C for five days. While growth of the *Pandoraea* cultures was scant under these conditions, it was nonetheless reproducible. Similarly, Daneshvar et al. (2001) also reported on the growth of nine *Pandoraea* isolates in a candle jar atmosphere. Collectively, these data would seem to indicate that at least some *Pandoraea* species might well be facultative anaerobes.

To gain an insight into the virulence mechanisms of *Pandoraea* species, it was decided to sequence the genomes of the two *P. apista* isolates recovered from this patient 11 months apart. Much to our surprise, the 16S rRNA sequence component of the genomes from both the February 2012 and January 2013 isolates identified them as *Pandoraea pnomenusa* (Ee et al., 2015). It is necessary to point out here that misidentification of *Pandoraea* species by MALDI-TOF MS alone is not uncommon because this method relies upon databases that are generated for microorganisms routinely recovered from clinical specimens. However, *Pandoraea* species are not routinely isolated or identified by the conventional microbiological methods available in many diagnostic laboratories; in turn, this makes creation of databases for these organisms that are necessary for accurate MALDI-TOF MS analyses somewhat problematic (Fernández-Olmos et al., 2012a). On review of the original MALDI-TOF MS identification scores, *P. apista* scored highest (2.090) followed by *P. pnomenusa* (1.614). The low score generated for *P. pnomenusa* (i.e., <1.7) would likely have been interpreted as being unreliable for species determination. The results described in this case report further underscore the limitations of using MALDI-TOF MS for differentiating *Pandoraea* species and suggest that until such time comprehensive databases are available, accurate identification of *Pandoraea* species will be dependent upon molecular characterization (Coenye and LiPuma, 2002; Schneider and Bauernfeind, 2015).

### DISCUSSION

Cystic fibrosis (CF) is an autosomal recessive disease, which can be caused by any one of the over 2000 mutations known to affect the cystic fibrosis transmembrane conductance regulator (CFTR) gene located on human chromosome 7. These mutations lead to an absent or dysfunctional chloride ion channel in respiratory epithelial cells, which in turn results in the accumulation of viscous respiratory secretions in the lungs of people with CF (Wilschanski et al., 1995). As a consequence, the airway of CF patients is intrinsically susceptible to colonization by a plethora of respiratory pathogens, and from very early on in life is colonized by bacterial pathogens including *S. aureus* and *P. aeruginosa* (Renders et al., 2001). These infections inevitably lead to pulmonary exacerbations and lung function decline. Despite aggressive antibiotic treatment, infection by *P. aeruginosa* eventually becomes chronic and is responsible for much of the morbidity and most of the mortality of people with CF (Hauser et al., 2011). Intriguingly, many “new” microorganisms are being isolated from and identified in respiratory secretions collected from CF patients due in part to improved laboratory diagnostic methods, although their contributions to disease progression are not yet known.

One group of bacteria currently considered to be emerging CF pathogens belongs to the genus *Pandoraea*. The genus *Pandoraea* was described by Coenye et al. (2000) to differentiate them from other already well-known CF pathogens, including *Pseudomonas* and two closely related Gram-negative rods, *Burkholderia* and *Ralstonia* species. In fact, phenotypic methods used by many microbiology laboratories commonly lead to the misidentification of *Pandoraea* species as either *Burkholderia* or

---

**TABLE 1 | *P. pnomenusa* antibiotic susceptibility testing by disk diffusion assay.**

| Antibiotic                        | Disc content (μg) | Zone diameter breakpoint for Resistance (mm) | Inhibition zone diameter (mm) | Resistant (R)/Susceptible (S) |
|-----------------------------------|-------------------|---------------------------------------------|-------------------------------|-----------------------------|
| Meropenem                         | 10                | ^a18                                         | 0                             | R                           |
| Amikacin                          | 30                | ^a15                                         | 0                             | R                           |
| Ciprofloxacin                     | 5                 | ^a22                                         | 0                             | R                           |
| Cefazidime                        | 10                | ^a16                                         | 0                             | R                           |
| Ticarcillin-clavulanic acid       | 85                | ^a18                                         | 8                             | R                           |
| Gentamicin                        | 10                | ^a15                                         | 0                             | R                           |
| Trimethoprim                      | 5                 | –                                            | 0                             | –                           |
| Aztreonam                         | 30                | ^a16                                         | 0                             | R                           |
| Tobramycin                        | 10                | ^a16                                         | 0                             | R                           |
| Cefepime                          | 30                | ^a18                                         | 0                             | R                           |
| Piperacillin-tazobactam           | 36                | ^a18                                         | 16                            | R                           |
| Trimethoprim-Sulphamethoxazole    | 25                | ^a16                                         | 28.5                          | ^S                          |

^a*Pseudomonas* spp. breakpoint.

^b*Stenotrophomonas* maltophilia breakpoint.

^cMinimum inhibitory concentration (MIC) of trimethoprim-sulfamethoxazole (cotrimoxazole, 12.5 μg/ml) determined by the broth dilution method.

---

Ambrose et al. Misidentification of Pandoraea
**REFERENCES**

Caraher, E., Collins, J., Herbert, G., Murphy, P. G., Gallagher, C. G., Crowe, M. J., et al. (2008). Evaluation of in vitro virulence characteristics of the genus *Pandoraea* in lung epithelial cells. *J. Med. Microbiol.* 57(Pt 1), 15–20. doi: 10.1099/jmm.0.47544-0

Coenye, T., Falsen, E., Hoste, B., Ohlé, M., Goris, J., Govan, Jr., et al. (2000). Description of *Pandoraea* gen. nov. with *Pandoraea apista* sp. nov., *Pandoraea pulmonicola* sp. nov., *Pandoraea pnomenusa* sp. nov., *Pandoraea sputorum* sp. nov. and *Pandoraea norimbergensis* comb. nov. *Int. J. Syst. Microbiol.* 50(Pt 2), 887–899. doi: 10.1099/00207713-50-2-887

---

**CONCLUDING REMARKS**

This case report further highlights the limitations associated with using MALDI-TOF MS and phenotypic-based testing for the identification of uncommon pathogens, and serves as an important caution for laboratories relying on these two methodologies for accurate identification of species of *Pandoraea*. Without consistent and reliable species level identification of multidrug-resistant *Pandoraea*, the clinical significance of these organisms will remain difficult to determine.

**AUTHOR CONTRIBUTIONS**

MA and LR substantially contributed to the conception of the work, the acquisition, analysis and interpretation of data and drafting and critically revising the work. MA and LR also have final approval of the version to be published and agree to be accountable for all aspects of the work. RM, SW, SB, OS, BM, DS substantially contributed to the acquisition, analysis and interpretation of data and in drafting and critically revising the work.

**FUNDING**

This work was funded by a Royal Hobart Hospital Research Foundation (RHHRF) grant number R22664.
Coenye, T., and LiPuma, J. J. (2002). Use of the gyrB gene for the identification of Pandoraea species. FEMS Microbiol. Lett. 208, 15–19. doi: 10.1111/j.1574-6968.2002.tb11053.x

Daneshvar, M. I., Hollis, D. G., Steigerwalt, A. G., Whitney, A. M., Spangler, L., Douglas, M. P., et al. (2001). Assignment of CDC weak oxidizer group 2 (WO-2) to the genus Pandoraea and characterization of three new Pandoraea genomospecies. J. Clin. Microbiol. 39, 1819–1826. doi: 10.1128/JCM.39.1819-1826.2001

EE, R., Ambrose, M., Lazenby, J., Williams, P., Chan, K. G., and Roddam, L. (2015). Genome sequences of two Pandoraea pnomenusa isolates recovered 11 months apart from a cystic fibrosis patient. Genome Announc. 3:e01389-14. doi: 10.1128/genomeA.01389-14

Fernández-Olmos, A., García-Castillo, M., Morosini, M. I., Lamas, A., Máiz, L., and Canton, R. (2012b). MALDI-TOF MS improves routine identification of non-fermenting Gram negative isolates from cystic fibrosis patients. J. Cyst. Fibros. 11, 59–62. doi: 10.1016/j.jcf.2011.09.001

Fernández-Olmos, A., Morosini, M. I., Lamas, A., García-Castillo, M., García-García, L., Cantón, R., et al. (2012a). Clinical and microbiological features of a cystic fibrosis patient chronically colonized with Pandoraea sp. sporum identified by combining 16S rRNA sequencing and matrix-assisted laser desorption ionization-time of flight mass spectrometry. J. Clin. Microbiol. 50, 1096–1098. doi: 10.1128/JCM.05730-11

Hauser, A. R., Jain, M., Bar-Meir, M., and McColey, S. A. (2011). Clinical significance of microbial infection and adaptation in cystic fibrosis. Clin. Microbiol. Rev. 24, 29–70. doi: 10.1128/CMR.00036-10

Henry, D. A., Mahenthiralingam, E., Vandamme, P., Coenye, T., and Speert, D. P. (2001). Phenotypic methods for determining genomovar status of the Burkholderia cepacia complex. J. Clin. Microbiol. 39, 1073–1078. doi: 10.1128/JCM.39.3.1073-1078.2001

Johnson, L. N., Han, J. Y., Moskowitz, S. M., Burns, J. L., Qin, X., and Enlund, J. A. (2004). Pandoraea bacteremia in a cystic fibrosis patient with associated systemic illness. Pediatr. Infect. Dis. J. 23, 881–882. doi: 10.1097/01.inf.0000136857.74561.3c

Jørgensen, I. M., Johansen, H. K., Frederiksen, B., Pressler, T., Hansen, A., Vandamme, P., et al. (2003). Epidemic spread of Pandoraea apista, a new pathogen causing severe lung disease in cystic fibrosis patients. Pediatr. Pulmonol. 36, 439–446. doi: 10.1002/ppul.10383

Kolpen, M., Hansen, C. R., Bjarnsholt, T., Moser, C., Christensen, L. D., van Gennip, M., et al. (2010). Polymorphonuclearleucocytes consume oxygen in sputum from chronic Pseudomonas aeruginosa pneumonia in cystic fibrosis. Thorax 65, 57–62. doi: 10.1136/thx.2009.114512

Lim, Y. L., Ee, R., Yong, D., Yu, C. Y., Ang, G. Y., Tee, K. K., et al. (2016). Complete genome sequence analysis of Pandoraea pnomenusa type strain DSM 16536(T) isolated from a cystic fibrosis patient. Front. Microbiol. 7:109. doi: 10.3389/fmicb.2016.00109

LiPuma, J. J. (2010). The changing microbial epidemiology in cystic fibrosis. Clin. Microbiol. Rev. 23, 299–323. doi: 10.1128/CMR.00068-09

Renders, N., Verbrugh, H., and Van Belkum, A. (2001). Dynamics of bacterial colonisation in the respiratory tract of patients with cystic fibrosis. Infect. Genet. Evol. 1, 29–39. doi: 10.1016/S1567-1348(01)00004-1

Schneider, I., and Bauernfeind, A. (2015). Intrinsic carbapenem-hydrolyzing oxacillinas from members of the genus Pandoraea. Antimicrob. Agents Chemother. 59, 7136–7141. doi: 10.1128/AAC.01112-15

Schobert, M., and Tielen, P. (2010). Contribution of oxygen-limiting conditions to persistent infection of Pseudomonas aeruginosa. Future Microbiol. 5, 603–621. doi: 10.2217/fmb.10.16

Striyevski, M. E., LiPuma, J. J., Messier, R. H. Jr., Rele, L. B., and Alexander, B. D. (2003). Sepsis, multiple organ failure, and death due to Pandoraea pnomenusa infection after lung transplantation. J. Clin. Microbiol. 41, 2255–2257. doi: 10.1128/JCM.41.5.2255-2257

Tunney, M. M., Field, T. R., Moriarity, T. F., Patrick, S., Doering, G., Muhlebach, M. S., et al. (2008). Detection of anaerobic bacteria in high numbers in sputum from patients with cystic fibrosis. Am. J. Respir. Crit. Care Med. 177, 995–1001. doi: 10.1164/rccm.200708-1151OC

Wilcanski, M., Zielenski, J., Markiewicz, D., Tsui, L. C., Corey, M., Levison, H., et al. (1995). Correlation of sweat chloride concentration with classes of the cystic fibrosis transmembrane conductance regulator gene mutations. J. Pediatr. 127, 705–710. doi: 10.1016/S00022447(95)0157-5

Wortitzsch, D., Tarran, R., Ulrich, M., Schwab, U., Cekici, A., Meyer, K. C., et al. (2002). Effects of reduced mucus oxygen concentration in airway Pseudomonas infections of cystic fibrosis patients. J. Clin. Invest. 109, 317–325. doi: 10.1172/JCI13870

Conflict of Interest Statement: The authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest.

Copyright © 2016 Ambrose, Malley, Warren, Beggs, Swallow, McEwan, Stock and Roddam. This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) or licensor are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms.